Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viking’s Oral Weight-Loss Drug Shows Early Efficacy/Safety Promise

Executive Summary

An oral formulation of the GLP-1/GIP analog VK2735 showed up to 5.3% reduction in body weight after four weeks in a Phase I study, with a nearly pristine safety and tolerability profile.

You may also be interested in...



A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian

Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.

Madrigal Has A Slow, Steady Launch Planned For Rezdiffra

Madrigal faces the challenge of opening the metabolic-associated steatohepatitis (MASH, also known as NASH) market, but the firm has been laying groundwork for over a year.

Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio

During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC150015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel